Tags : Sandoz

Insights+

Insights+ Key Biosimilars Events of February 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of Feb, Biocon collaborated with CHAI to expand access […]Read More

Biosimilars

Sandoz Launches Hyrimoz (biosimilar, adalimumab) in Canada

Shots: The company expands its portfolio with the marketing of the 5th biosimilars in Canada. Hyrimoz is indicated for use in nine indications of the reference (Humira) in the field of rheumatology, gastroenterology and dermatology Sandoz Canada has completed the pCPA negotiations for Hyrimoz, which is the first step in securing public reimbursement Hyrimoz is […]Read More

M&A

Novartis to Acquire GSK’s Cephalosporin Antibiotics Business

Shots: GSK to receive $350M at closing, along with ~$150M as milestones. The transaction is expected to close in H2’21 The transaction will allow GSK to prioritize and simplify its portfolio and invest in the company’s R&D pipeline and new product launches The agreement includes the global rights to three established brands (Zinnat, Zinacef, and […]Read More

Insights+

Insights+ Key Biosimilars Events of December 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients. Hence, the providers are more likely to adopt biosimilars as a “reference […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshots (Dec 14-18, 2020)

Sandoz to Launch Hyrimoz (biosimilar, adalimumab) in Canada Published: Dec 17, 2020 | Tags: Authorization, Biosimilar, canada, health, Humira, Hyrimoz, Launch, receives, Sandoz Amgen’s Riabni (biosimilar, rituximab) Receives the US FDA’s Approval for Multiple Diseases Published: Dec 17, 2020 | Tags: Adult, Amgen, approval, Biosimilar, CLL, GPA, MPA, NHL, patients, receives, RIABNI, Rituxan, Rituximab, rituximab-arrx, […]Read More

Biosimilars

Sandoz to Launch Hyrimoz (biosimilar, adalimumab) in Canada

Shots: Health Canada has authorized Hyrimoz on Nov 4, 2020 for marketing in Canada. Hyrimoz has been approved for use in all same indications as reference Humira, including rheumatology, gastroenterology and dermatology A patient support program will be available to patients treated with Hyrimoz providing guidance with reimbursement navigation, financial assistance, administrative support & education […]Read More

Top 20

Top 20 Generics Pharma Companies Based On 2019 Revenue

The global generics pharmaceutical market has become an intimidating segment of the pharmaceutical drug market which continuously growing and increasing with its accessibility & benefits offered as efficient and economical drugs. Generics are approved copies of small molecule drugs that contain the same amount of active ingredients, dosage form, safety, strength, route of administration, quality, […]Read More

Biosimilars Insights+

Insights+ Key Biosimilars Events of June 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Mylan with its partners Lupin and Biocon received MAA for Nepexto (biosimilar, etanercept) in EU and the US FDA’s Approval for Semglee (biosimilar, insulin glargine) respectively Our team at PharmaShots has summarized 15 key events of the […]Read More

Insights+

PharmaShots’ Key Highlights of Second Quarter 2020

The second quarter of 2020 has ended with big approvals in pharma and biotech industry. Moving with the latest approval of Roche’s Phesgo and Enspryng & Zogenix’s Fintepla. Highlights of the quarter is COVID-19 as the development of vaccines and drugs were on peak. Celltrion evaluated Remsima (biosimilar, infliximab) against COVID-19 in the UK. The […]Read More